Liquid biopsies are diagnostic tests that analyze circulating tumor DNA (ctDNA) found in a patient's blood. These tests can provide insights into the genetic makeup of a tumor without requiring a tissue biopsy.
Liquid biopsies address the limitations of traditional tissue biopsies, such as invasiveness, cost, and time required to obtain a sample. They also enable repeated monitoring of patients over time without additional invasive procedures.
High-sensitivity sequencing technologies are used to detect and quantify ctDNA, which is fragmented genetic material shed by tumors into the bloodstream. This allows for the identification of specific mutations or other genetic alterations associated with cancer.
Manufacturers produce reagents, consumables, and sequencing machines for ctDNA analysis. The process involves developing high-sensitivity sequencing technologies and optimizing protocols for blood sample collection and processing.
The build process includes sample preparation (e.g., plasma isolation), library preparation, sequencing, data analysis, and interpretation of results. Each step requires precise handling to ensure the integrity of ctDNA samples.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.